VENITI, Inc., a leader in the advancement of treatment for deep venous disease, has closed on USD 25 million in Series D equity financing from Boston Scientific Corporation. The funds will allow VENITI to complete the VIRTUS Trial and regulatory filing for the VICI VENOUS STENT System. The trial is being performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE). The company also intends to expand product development and commercial operations.

'We are extremely pleased to be partnering with such a high-quality industry leader to advance our core technology, the VICI VENOUS STENT, this financing will allow us to complete a number of critical milestones and support more physicians treating patients suffering from venous outflow obstruction around the world.'

Jeff Elkins

President and Chief Executive Officer,

VENITI


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version